Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs

Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs

The overall incidence of bladder cancer in the seven major markets is forecast to exceed 160,000 by the end of 2008. Treatment of bladder cancer employs mainly immunotherapy and chemotherapy. However, both these methods are ineffective in improving long-term survival. Thus, there is a lucrative commercial opportunity for drug developers to enter this market, especially in the metastatic setting.

Current diagnosis and treatment of bladder cancer, including treatment regimens by stage and geographical location

Issues in diagnosis, treatment strategies and unmet needs

Examination of pipeline activity and potential future opportunities for drug developers

Stakeholder opinions based on qualitative interviews with five opinion leaders from the US and Europe

Discovery of more effective systemic therapies is crucial for the treatment of patients with advanced or metastatic disease as current therapies have little impact on survival.

BCG therapy, the current standard treatment for non-invasive bladder cancer has limited use in patients who experience multiple recurrences. Patients who become refractory or intolerant to further BCG treatment have few options. There is therefore a large patient potential for drugs that can replace BCG or treat BCG-refractory patients.

Bladder cancer therapy consists of cytotoxics and immunotherapy agents that have been genericized for many years. Late-stage pipeline drugs consist of targeted therapies and cytotoxics including Urocidin and EOquin. Some late stage drugs have demonstrated favourable efficacy in trials and look to fill some of the unmet needs in bladder cancer.

Understand the pathology and epidemiology of bladder cancer

Understand the limitations of current bladder cancer treatment

Obtain insight into the commercial opportunities available in the bladder cancer market

Publication: 39753
Library Code: DMHC2466
Type: Report
Format: PDF
Pages: 95

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions